Prodrugs of heteroaryl compounds

Abstract

The present invention provides hydrophobic prodrugs of bases, nucleosides, and nucleotides as well as methods of using the prodrugs as antiviral and anti-cancer chemotherapeutic agents.

1 . A compound having a structure according to Formula I:  
       
         
           
           
               
               
           
         
       
       wherein 
 a is either 0 or 1;  
 the dashed line represents a double bond between C* and N when a is 0;  
 R 2  is a member selected from (═O) and NR 7 R 8 ;  
 R 4  is a member selected from H, halogen, OR 3 , NR 7 R 8 , halogen, nitrile, and substituted and unsubstituted (C 1 -C 5 )alkyl;  
 R 6  is a member selected from H, halogen, OR 3 , NR 3 R 3 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7-membered cycloalkyl, substituted or unsubstituted 5- to 7-membered heterocycloalkyl, substituted or unsubstituted acyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;  
 R 7 , R 8 , R 5  and R 1  are members independently selected from H, OR 3 , NR 3 R 3 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7-membered cycloalkyl, substituted or unsubstituted 5- to 7-membered heterocycloalkyl, substituted or unsubstituted acyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl;  
 R 3  is independently selected from H, substituted or unsubstituted alkyl and substituted or unsubstituted acyl;  
 wherein R 7  and R 8  together with the nitrogen to which they are joined optionally form a substituted or unsubstituted 5- to 7-membered ring;  
 wherein R 8  and R 5  together with the atoms to which they are joined optionally form a substituted or unsubstituted 5- to 7-membered ring;  
 wherein R 5  and R 6  together with the atoms to which they are joined optionally form a substituted or unsubstituted 5- to 7-membered ring; and  
 wherein at least one member selected from R 3 , R 5 , R 7 , and R 8 , alone or together with the atom to which it is covalently bonded, is selected from carbamate and urea linkers.  
 
     
     
         2 . The compound according to  claim 1 , wherein R 2  is selected from (═O), —NH 2 , and —NHOH.  
     
     
         3 . The compound according to  claim 1 , wherein R 4  is selected from F, CN, —CCH, —CCMe, and CH 3 .  
     
     
         4 . The compound of  claim 1 , wherein R 1  comprises a hydroxyl moiety.  
     
     
         5 . The compound of  claim 4 , wherein R 1  comprises a saccharyl moiety.  
     
     
         6 . The compound of  claim 1 , wherein R 1  is a structure according to Formula II:  
       
         
           
           
               
               
           
         
       
       wherein 
 the dashed line represents a double bond between C a  and C b ;  
 R 9 , R 10  and R 11  are members independently selected from H, —OH, —OR 12 , —NH 2 , —NO 2 , —SO 2 NH 2 , N 3 , halogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7-membered cycloalkyl, substituted or unsubstituted 5- to 7-membered heterocycloalkyl, substituted or unsubstituted acyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; 
 wherein R 12  is selected from an amino acid and a peptide comprising between 2 and 5 amino acids;  
 
 wherein R 9  and R 10  together with the atoms to which they are joined optionally form a substituted or unsubstituted 5- to 7-membered ring; 
 wherein R 10  and R 11  together with the atoms to which they are joined optionally form a substituted or unsubstituted 5- to 7-membered ring.  
 
 
     
     
         7 . The compound according to  claim 6 , wherein R 9 , R 10  and R 11  are members independently selected from H, OH, (R 13 ) 3 SiO—, and a structure according to Formula III:  
       
         
           
           
               
               
           
         
         wherein each R 13  is independently selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted 3- to 7-membered cycloalkyl, substituted or unsubstituted 5- to 7-membered heterocycloalkyl, substituted or unsubstituted acyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl; 
 wherein more than one R 13  together with the atoms to which they are joined optionally form a substituted or unsubstituted 5- to 7-membered ring; and  
 
         wherein R 16 , R 17 , and R 18  are independently selected from substituted and unsubstituted alkyl.  
       
     
     
         8 . The compound of  claim 7 , wherein R 16 , R 17 , and R 18  are ethyl.  
     
     
         9 . The compound according to  claim 1 , wherein R 3 , R 5 , R 7 , and R 8  are independently selected from H and a structure according to Formula IV:  
       
         
           
           
               
               
           
         
         wherein R 14  is selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted acyl, substituted or unsubstituted aryl, and substituted or unsubstituted heteroaryl, an amino acid, and a peptide comprising between 2 and 5 amino acids;  
         wherein if R 8  is a structure according to Formula IV, then R 7  is H.  
       
     
     
         10 . The compound according to  claim 1 , wherein R 3 , R 5 , R 7 , and R 8  are independently selected from H and a structure according to Formula V:  
       
         
           
           
               
               
           
         
         wherein R 15  is selected from substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted acyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, an amino acid, and a peptide comprising between 2 and 5 amino acids;  
         wherein if R 8  is a structure according to Formula V, then R 7  is H.  
       
     
     
         11 . The compound according to  claim 9 , wherein R 14  is selected from substituted or unsubstituted (C 4 -C 12 )alkyl, benzyl, 2-nitro-furanyl, retinol, α-tocopherol, calciferol, vitamin K, cholesterol,  
       
         
           
           
               
               
           
         
       
     
     
         12 . The compound according to  claim 10 , wherein R 15  is selected from substituted or unsubstituted (C 4 -C 12 )alkyl, benzyl, 2-nitro-furanyl, retinol, α-tocopherol, calciferol, vitamin K, cholesterol,  
       
         
           
           
               
               
           
         
       
     
     
         13 . The compound according to  claim 11 , wherein R 14  is unsubstituted (C 6 -C 10 )alkyl.  
     
     
         14 . The compound according to  claim 12 , wherein R 15  is unsubstituted (C 6 -C 10 )alkyl.  
     
     
         15 . The compound according to  claim 9 , wherein R 2 is selected from (═O), —NH 2 , and —NHOH.  
     
     
         16 . The compound according to  claim 10 , wherein R 2  is selected from (═O), —NH 2 , and —NHOH.  
     
     
         17 . The compound according to  claim 9 , wherein R 4  is selected from —F, —CN, —CCH, —CCMe, and —CH 3 .  
     
     
         18 . The compound according to  claim 10 , wherein R 4  is selected from —F, —CN, —CCH, —CCMe, and —CH 3 .  
     
     
         19 . The compound according to  claim 11 , wherein 
 R 2  is selected from (═O), —NH 2 , and —NHOH; and    R 4  is selected from —F, —CN, —CCH, —CCMe, and —CH 3 .    
     
     
         20 . The compound according to  claim 12 , wherein 
 R 2  is selected from (═O), —NH 2 , and —NHOH; and    R 4  is selected from -F, —CN, —CCH, —CCMe, and —CH 3 .    
     
     
         21 . A method for treating a viral disease comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound according to  claim 1 .  
     
     
         22 . The method of  claim 21 , wherein said compound is given orally.  
     
     
         23 . The method of  claim 22 , wherein said compound is an enteric formulation.  
     
     
         24 . The method of  claim 23 , wherein said compound is delivered in an osmotic oral delivery device.  
     
     
         25 . The method of  claim 21 , wherein the viral disease is caused by a virus selected from a RNA virus and a DNA virus.  
     
     
         26 . The method of  claim 25 , wherein said virus is selected from a retrovirus and a ribovirus.  
     
     
         27 . The method of  claim 26 , wherein said retrovirus is selected from HIV and Hepatitis B.  
     
     
         28 . The method of  claim 26 , wherein said ribovirus is Hepatitis C.  
     
     
         29 . A method for treating cancer comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound according to  claim 1 .  
     
     
         30 . The method of  claim 29 , wherein said cancer is a hematopoietic cancer.  
     
     
         31 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to Formula I.